Johnson & Johnson Emerges as a Top Defensive Dividend Stock

When searching for defensive dividend stocks, the healthcare sector is often the best place to start. This industry is inherently recession-resistant, as people always need medical care, whether it's for medicine, surgery, or innovative treatments.

Among the many healthcare stocks, Johnson & Johnson (JNJ) stands out as a top choice for long-term investors. The company has an impressive track record of raising its quarterly cash dividend for 64 consecutive years, earning it a spot among the Dividend Kings. These stocks are recognized for having at least 50 years of consecutive annual dividend growth.

Johnson & Johnson's commitment to dividend growth is backed by strong operational performance. The company has strategically shifted its focus toward faster-growing segments of healthcare, such as hematology, while divesting slower-growing businesses. This approach helps sustain the revenue and earnings growth needed to support dividend increases and maintain the stock's valuation around 21 times forward earnings.

Looking at total returns, which combine price appreciation and cash returns from dividends, Johnson & Johnson presents a compelling case. The stock trades at a forward payout ratio of under 50%, which is considered sustainable. The company's dividend yield is modest at 2.1%, with annual payout growth in the mid-single-digits. While not the most exciting combination, these factors suggest solid total returns over the long term.